Peer-reviewed veterinary case report
Ultrasound spleen and liver tests predict survival in dogs with skin
By Stefanello, D et al.·Published in Journal of veterinary internal medicine·2009·Dipartimenti di Scienze Cliniche Veterinarie·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor.
- Species:
- dog
Plain-English summary
A group of 52 dogs diagnosed with skin tumors called cutaneous mast cell tumors (cMCT) underwent ultrasound-guided tests to check for cancer spread to the spleen and liver. The results showed that dogs with cancer spread to these organs had significantly shorter survival times—only about 34 days—compared to those without spread, who lived an average of 733 days. This suggests that testing the spleen and liver can help predict how long a dog might live after being diagnosed with cMCT. If your dog has been diagnosed with cMCT, discussing ultrasound-guided cytology with your vet could be important for understanding their prognosis.
People also search for: dog mast cell tumor prognosis · ultrasound for dog cancer · cutaneous mast cell tumor treatment
Abstract
BACKGROUND: In the clinical staging of cutaneous mast cell tumors (cMCT), the diagnosis of metastasis is controversial based on cytological examination of lymph nodes, spleen, liver, bone marrow, and blood. OBJECTIVES: To define the prognostic role of ultrasound-guided cytology of spleen and liver in cMCT. The results of cytological evaluation were compared in relation with survival time. ANIMALS: Fifty-two client-owned dogs with a diagnosis of cMCT. METHODS: Selection of cases was based on cytological evaluation of liver and spleen to detect infiltration at distant sites. The Kaplan Meier method was used to compare survival in dogs with and without infiltration of spleen and liver (log-rank test P < .05). RESULTS: Ten dogs with cMCT had mast cell infiltration of spleen, liver, or both and 4 of these dogs had involvement of the regional lymph nodes. The majority of dogs had 2 or more ultrasonographically abnormal findings simultaneously in spleen and liver. Nine dogs had grade II cMCT, and 1 had grade III cMCT. Dogs with positive evidence of mast cell infiltration to spleen, liver, or both had shorter survival times (34 versus 733 days) compared with dogs negative for mast cell infiltration at distant sites. CONCLUSION AND CLINICAL IMPORTANCE: Dogs with evidence of mast cell infiltration at distant sites have a shorter survival times than dogs without evidence of infiltration at distant sites. This study suggests that cytology of spleen and liver is indicated either for ultrasonographically normal or for ultrasonographically abnormal spleen and liver in dogs with cMCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19656285/